Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Tuesday, 9 July 2013
AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research AstraZeneca today announced that it has entered into an agreement with the University of Cambridge
Friday, 28 June 2013
AstraZeneca Completes Acquisition Of Pearl Therapeutics AstraZeneca today announced that on 27 June 2013 it completed its acquisition of Pearl Therapeutics
Monday, 17 June 2013
MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity MedImmune and NGM will jointly advance first-in-class peptide and antibody drug candidates based on the discovered EEC hormones
Download our brochure

Download your comprehensive guide to partnering with us.

Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar